|Bid||5.80 x 3000|
|Ask||6.20 x 4000|
|Day's Range||5.57 - 5.99|
|52 Week Range||3.43 - 10.88|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.79|
WALTHAM, Mass., August 02, 2021--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.